Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

61 results about "Tumor Load" patented technology

Tumor load listen (TOO-mer lode) Refers to the number of cancer cells, the size of a tumor, or the amount of cancer in the body.

Multi-modal, multi-resolution deep learning neural networks for segmentation, outcomes prediction and longitudinal response monitoring to immunotherapy and radiotherapy

Systems and methods for multi-modal, multi-resolution deep learning neural networks for segmentation, outcomes prediction and longitudinal response monitoring to immunotherapy and radiotherapy are detailed herein. A structure-specific Generational Adversarial Network (SSGAN) is used to synthesize realistic and structure-preserving images not produced using state-of-the art GANs and simultaneously incorporate constraints to produce synthetic images. A deeply supervised, Multi-modality, Multi-Resolution Residual Networks (DeepMMRRN) for tumor and organs-at-risk (OAR) segmentation may be used for tumor and OAR segmentation. The DeepMMRRN may combine multiple modalities for tumor and OAR segmentation. Accurate segmentation is may be realized by maximizing network capacity by simultaneously using features at multiple scales and resolutions and feature selection through deep supervision. DeepMMRRN Radiomics may be used for predicting and longitudinal monitoring response to immunotherapy. Auto-segmentations may be combined with radiomics analysis for predicting response prior to treatment initiation. Quantification of entire tumor burden may be used for automatic response assessment.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

Multi-modal, multi-resolution deep learning neural networks for segmentation, outcomes prediction and longitudinal response monitoring to immunotherapy and radiotherapy

Systems and methods for multi-modal, multi-resolution deep learning neural networks for segmentation, outcomes prediction and longitudinal response monitoring to immunotherapy and radiotherapy are detailed herein. A structure-specific Generational Adversarial Network (SSGAN) is used to synthesize realistic and structure-preserving images not produced using state-of-the art GANs and simultaneously incorporate constraints to produce synthetic images. A deeply supervised, Multi-modality, Multi-Resolution Residual Networks (DeepMMRRN) for tumor and organs-at-risk (OAR) segmentation may be used for tumor and OAR segmentation. The DeepMMRRN may combine multiple modalities for tumor and OAR segmentation. Accurate segmentation is may be realized by maximizing network capacity by simultaneously using features at multiple scales and resolutions and feature selection through deep supervision. DeepMMRRN Radiomics may be used for predicting and longitudinal monitoring response to immunotherapy. Auto-segmentations may be combined with radiomics analysis for predicting response prior to treatment initiation. Quantification of entire tumor burden may be used for automatic response assessment.
Owner:MEMORIAL SLOAN KETTERING CANCER CENT

System for and method of determining cancer prognosis and predicting response to therapy

A database for predicting clinical outcomes based upon quantitative tumor burden in lymph node samples from an individual is provided. The database comprises data sets from a plurality of individuals. The data sets include clinical outcome data and data regarding number of lymph nodes evaluated, maximum number of biomarker detected in any single node, median normalized expression levels detected across all evaluated lymph nodes and the maximum normalized expression levels detected in any evaluated lymph nodes and the database also includes stratified risk categories based upon recursive partitioning of data. A system for predicting clinical outcomes based upon quantitative tumor burden in lymph node samples from an individual is provided which includes the database linked to a data processor, an input interface and an output interface. Method of preparing a database and method for predicting clinical outcome for a test patient based upon quantitative tumor burden in lymph node samples from an individual using a system that includes the database linked to a data processor, an input interface and an output interface. The method comprises measuring quantitative tumor burden in a plurality of lymph node samples from an individual, inputting the results into the system and processing with data in the database. The results of the processing of the data is the assignment of data test patient to a stratified risk category. Output is produced that displays test patient's identity and assigned stratified risk category.
Owner:THOMAS JEFFERSON UNIV

Late breast cancer survival probability prediction nomogram, survival probability prediction method and patient classification method

The invention provides a late breast cancer survival probability prediction nomogram, a survival probability determination method and a patient classification method. The nomogram comprises a score scale and a plurality of prognostic variables, and the prognostic variables are classification variables and comprise a breast cancer staging variable, a breast cancer molecular typing variable, a patient disease-free recurrence time variable, a tumor load variable and a brain metastasis variable; each prognostic variable comprises a plurality of variable values, and each variable value correspondsto one score on the score scale; the nomogram also comprises a total score scale and patient survival probability variables which are continuous variables and comprise a one-year survival probabilityvariable, a two-year survival probability variable and a three-year survival probability variable, wherein each survival probability variable comprises a variable value range, and each variable valuerange has a score range corresponding to the total score scale; the development of medical science is considered, and meanwhile, the requirements of domestic patients are considered, so that the evaluation accuracy of the advanced breast cancer is improved.
Owner:SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV

United medicine composition for resisting double-hit lymphomas and application of united medicine composition for resisting double-hit lymphomas

The invention relates to a united medicine composition for resisting double-hit lymphomas and application of the united medicine composition for resisting double-hit lymphomas. The united medicine composition comprises a medicine Venetoclax and a medicine Chiauranib. According to the united medicine composition disclosed by the invention, the medicine Venetoclax and the medicine Chiauranib are creatively united to be used as the united medicine composition for resisting double-hit lymphomas; the inventor finds that the united medicine composition for resisting double-hit lymphomas has significant killing effects on varied DHL cell strains, and presents concentration dependence and time dependence; the research result of in vitro tumor formation experiment also proves that the united medicine composition for resisting double-hit lymphomas can restrain the growth of DHL cells in vivo, alleviates tumor load and immersion degree, and does not have obvious toxic and side effects; and the united medicine composition for resisting double-hit lymphomas has higher activity for resisting double-hit lymphomas than single Venetoclax or single Chiauranib, and can more effectively restrain the growth of in vivo tumors, and a new strategy and thought are provided for the treatment of the resisting double-hit lymphomas.
Owner:THE FIRST AFFILIATED HOSPITAL OF XIAMEN UNIV +2
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products